Mast Therapeutics Inc (MSTX) : Proquest Associates Iv has sold out all of its stake in Mast Therapeutics Inc during the most recent quarter, according to the disclosure filed by the company on May 13, 2016 with the SEC. The investment management company has sold out 1,275,925 shares of Mast Therapeutics Inc which is valued at $377,674.
Other Hedge Funds, Including , Renaissance Technologies added MSTX to its portfolio by purchasing 21,470 company shares during the most recent quarter which is valued at $6,355. Raymond James Associates added MSTX to its portfolio by purchasing 13,795 company shares during the most recent quarter which is valued at $4,083.Blackrock Fund Advisors boosted its stake in MSTX in the latest quarter, The investment management firm added 6,006 additional shares and now holds a total of 31,142 shares of Mast Therapeutics Inc which is valued at $9,218.
Mast Therapeutics Inc opened for trading at $0.307 and hit $0.3499 on the upside on Wednesday, eventually ending the session at $0.34, with a gain of 11.29% or 0.0345 points. The heightened volatility saw the trading volume jump to 51,26,054 shares. Company has a market cap of $66 M.
Mast Therapeutics Inc. is a clinical-stage biopharmaceutical company. The Company develops therapies for serious or life-threatening diseases with unmet needs. The Company leverages its Molecular Adhesion and Sealant Technology (MAST) platform to develop MST-188 (vepoloxamer) Injection the Company’s lead product candidate. Vepoloxamer is being tested in a Phase III clinical study called EPIC for the treatment of vaso-occlusive crisis in patients with sickle cell disease. The Company also develops AIR001 a sodium nitrite solution for intermittent inhalation through nebulizer. AIR001 is being tested in multiple institution-sponsored Phase IIa clinical studies that provide the Company with data on AIR001’s potential to treat patients with preserved ejection fraction (HFpEF).